Cyrano Therapeutics' Phase 2 FLAVOR Trial Selected to Open 72nd Annual Meeting of the American Rhinologic Society (ARS)

Phase 2CYR-064Positive

AI Analysis

Summary

Cyrano Therapeutics announced that Phase 2 FLAVOR trial results for CYR-064 have been selected to open the General Session at the 72nd Annual Meeting of the American Rhinologic Society. The company is developing novel treatments for smell and taste disorders.

Clinical Trial Data

Phase

Phase 2

Outcome Details

Phase 2 FLAVOR trial results selected to open General Session at 72nd Annual Meeting of the American Rhinologic Society

Importance:5/10

Sentiment:

0.50

regenerative medicinesmell disorderstaste disordersclinical-stageconference presentation

Related Companies

$AHR $SHWZ

Read the original article

Published by PR Newswire Biotech on October 8, 2026 12:10 PM

Read Original